You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.
CHAIR
Dr. Suresh Ambudkar
NCI, National Institutes of Health, MD
CO-CHAIR
Dr. Huang Chiao (Joe) Huang
University of Maryland, MD

The phenomenon of multidrug resistance (MDR) in cancer is multifactorial and several different mechanisms are involved in the development of intrinsic or acquired resistance to chemically different anticancer drugs. The expression of ABC drug transporters is one of the main causes of cancer chemoresistance. Recently, tremendous progress has been made in understanding the mechanism of drug transport by these ABC drug transporters. In addition, several studies have demonstrated that the unique tumoricidal effects of photodynamic therapy (PDT) can overcome cancer drug resistance and sensitize tumor cells to standard therapies. Photodynamic therapy involves light activation of a drug, called a photosensitizer, to generate a reactive molecular species that kills cancer cells or modulates the tumor microenvironment. PDT can not only be used as a local treatment but can also trigger potent systemic antitumor activity. This symposium will highlight several promising therapies including use of repurposed drugs, dual inhibitors, PDT, and nanomedicine to overcome MDR to improve the efficiency of both standard and multi-modality therapeutics to combat cancer.

Speakers

Tayyaba Hasan
Tayyaba Hasan

Harvard Medical School, Boston, MA